Wellington Management Group LLP Decreases Stock Holdings in Janux Therapeutics, Inc. $JANX

Wellington Management Group LLP trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 5.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,507,360 shares of the company’s stock after selling 90,290 shares during the quarter. Wellington Management Group LLP’s holdings in Janux Therapeutics were worth $23,153,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Nano Cap New Millennium Growth Fund L P purchased a new position in Janux Therapeutics during the 4th quarter valued at about $34,000. Versant Capital Management Inc lifted its holdings in Janux Therapeutics by 42.8% in the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock worth $40,000 after buying an additional 784 shares during the period. Osaic Holdings Inc. grew its position in shares of Janux Therapeutics by 704.6% in the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock worth $80,000 after buying an additional 3,037 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Janux Therapeutics during the fourth quarter valued at approximately $51,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Janux Therapeutics by 175.5% during the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares during the period. 75.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

JANX has been the subject of a number of research analyst reports. Guggenheim dropped their price target on Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a report on Monday, August 24th. Stifel Nicolaus set a $35.00 target price on shares of Janux Therapeutics in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. Finally, Evercore set a $22.00 price target on shares of Janux Therapeutics in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $36.46.

Janux Therapeutics Trading Up 2.2%

Shares of Janux Therapeutics stock opened at $20.24 on Friday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -12.34 and a beta of 2.53. The business has a fifty day simple moving average of $16.59 and a two-hundred day simple moving average of $15.03. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million for the quarter, compared to analysts’ expectations of $19.07 million. Analysts predict that Janux Therapeutics, Inc. will post -1.76 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.